Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having ...

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read more here.

Alpha Cognition's ZUNVEYL targets Alzheimer's with improved tolerability over existing galantamine therapies. Read why I rate ...

Cognito’s OVERTURE trial demonstrated significant ‘time saved’ in functional and cognitive decline at both six and 18 months.

The combination of a recently approved blood test for detection of Alzheimer's disease combined with two medications that slow progression of the disease is drastically improving outcomes for patients ...

Get the latest business headlines including trade deals, AI in airlines, and the surprising comeback of cottage cheese. Stay ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.